CD8A and cancer: We previously found that administration of gene-modified T cells in clinical trials can elicit high-magnitude CD8+ and CD4+ responses to foreign transgene–encoded antigens, even in highly immunocompromised patients, which suggested that this could be a novel cell-based vaccine platform for cancer (22, 23).